Document is current
Any future updates will be listed below
-
Authors
McAndrews, Kathleen M https://orcid.org/0000-0002-4092-4991
Mahadevan, Krishnan K
Li, Bingrui
Comptdaer, Anaïs M
Sockwell, Amari M
Morse, Sami J
Kelly, Patience J
Patel, Sarah I
Kirtley, Michelle L
Moreno Diaz, Barbara A
Lyu, Hengyu
Peng, David H https://orcid.org/0000-0003-0511-1888
Khazaei, Sima
Schalck, Aislyn
Zhou, Xunian
Sugimoto, Hikaru
Bickert, Aaron A
Sthanam, Lakshmi Kavitha
Taylor, Meagan R
Kumbhar, Shreyasee V
Arian, Kent A
Barekatain, Yasaman
Paradiso, Francesca
Guerrero, Paola A
Bernard, Vincent
Sobhani, Navid
Camacho-Acevedo, Alondra N
Bornes, Kiara E
Tran, Phuong Thao
Maitra, Anirban
Heffernan, Timothy P
Kalluri, Raghu https://orcid.org/0000-0002-2190-547X
-
Funding
Funding for this research was provided by:
Break Through Cancer
Lustgarten Foundation
HHS | NIH | National Cancer Institute (P01 CA117969)
HHS | NIH | National Cancer Institute (U54CA274371)
HHS | NIH | National Cancer Institute (P30CA16672)
Ergon Foundation
Mullick Foundation
Shelby Lavine Scholar
Sid W. Richardson Foundation
- License Information
-
More Information
Article History
Received: 30 March 2026
Revised: 23 June 2026
Accepted: 26 June 2026
First Online: 11 July 2026
Disclosure and competing interests statement
: AM is listed as an inventor on a patent that has been licensed by Johns Hopkins University to Thrive Earlier Detection. TP Heffernan receives advisory fees from Cullgen Inc., Psivant Therapeutics, and Isomorphic Labs. The remaining authors declare no relevant competing interests.
